Therapy Based on Stage of Disease and Risk Assessment in Treating Children With Neuroblastoma

Launched by CHILDREN'S HOSPITAL MEDICAL CENTER, CINCINNATI · May 11, 2004

Keywords

ClinConnect Summary

OBJECTIVES: I. Increase the survival rates and duration of survival in children and adolescents with neuroblastoma by using stage- and risk group-appropriate therapy. II. Determine whether using cisplatin/etoposide/vindesine and vincristine/dacarbazine/ifosfamide/doxorubicin instead of cisplatin/teniposide and vincristine/dacarbazine/cyclophosphamide/doxorubicin improves remission rate and lessens toxicity in patients with stage 3C, 3D, or 4 neuroblastoma. III. Determine whether local radiotherapy to the primary tumor and bone metastasis improves local tumor control in these patients. IV. C...

Gender

ALL

Eligibility criteria

• • DISEASE CHARACTERISTICS: Neuroblastoma with diagnosis based on one of the following: Histologic confirmation Cytologic confirmation in bone marrow and elevated catecholamine metabolites Typical tumor appearance on CT, MRI, or ultrasound and: Unequivocal MIBG uptake in tumor Elevated catecholamines in serum or urine No primitive neuroectodermal tumor or primary intracerebral neuroblastoma Such patients referred to protocol GER-HIT90
• • PATIENT CHARACTERISTICS: Age: Under 21 Other: No serious cerebral trouble No severe concomitant disease, e.g.: No severe congenital malformation No severe organ function abnormality
• • PRIOR CONCURRENT THERAPY: No prior cytostatic therapy (e.g., for Wilms' tumor) No concurrent therapy